Background—Circulating levels of C-reactive protein (CRP) may constitute an independent
risk factor for cardiovascular disease. How CRP as a risk factor is involved in cardiovascular …

Currently, five anti-TNF biologic agents are approved for the treatment of rheumatoid arthritis
(RA): adalimumab, infliximab, etanercept, golimumab and certolizumab pegol. Formation of …

Dealing with immunogenicity of biologicals: assessment and c... : Current Opinion in
Rheumatology Dealing with immunogenicity of biologicals: assessment and clinical relevance …

To identify new genetic risk factors for rheumatoid arthritis, we conducted a genome-wide
association study meta-analysis of 5,539 autoantibody-positive individuals with rheumatoid …

Context Short-term data on the immunogenicity of monoclonal antibodies showed
associations between the development of antidrug antibodies and diminished serum drug …

Methods. Fifteen patients with primary SS were included in this phase II trial. Inclusion
criteria for the early primary SS group were B cell hyperactivity (IgG> 15 gm/liter), presence …

To identify rheumatoid arthritis risk loci in European populations, we conducted a meta-
analysis of two published genome-wide association (GWA) studies totaling 3,393 cases and …

To discover new rheumatoid arthritis (RA) risk loci, we systematically examined 370 SNPs
from 179 independent loci with P< 0.001 in a published meta-analysis of RA genome-wide …

Background: A substantial proportion of patients with rheumatoid arthritis (RA) do not
respond, or lose initial response, to adalimumab treatment. One explanation for non …

Background Rises in circulating C-reactive protein (CRP), the prototypical acute-phase
protein in humans, correlate with clinical outcome in patients with myocardial ischemia and …